相关实验视频

Updated: Jun 8, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

营养药物向雄激素受体-拼接变体 (AR-SV) 来管理抵抗割的前列腺癌 (CRPC)

Ashish Tyagi¹, Balaji Chandrasekaran¹, Vaibhav Shukla¹

¹Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M University, College Station, TX 77845, United States.

Pharmacology & therapeutics

|November 4, 2024

概括

天然化合物通过向雄激素受体变异来治疗晚期前列腺癌具有前景,为当前疗法提供了潜在的替代方案,副作用较少. 这种方法特别适用于耐化疗,耐割的前列腺癌 (CRPC).

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

前列腺癌的发展和进展是由雄激素受体 (AR) 激活驱动的.
目前针对AR结域 (LBD) 的抗雄激素疗法面临挑战,原因是由于AR-V7.7等AR拼接变体介导的不良影响和耐药性.
耐化疗,耐割的前列腺癌 (CRPC) 是一个重大的临床挑战.

研究的目的:

审查AR变体,特别是AR-V7在CRPC中的作用.
研究自然化合物及其衍生物在向AR及其拼接变体中的治疗潜力.
探索以天然产品为基础的策略,以克服晚期前列腺癌中抵抗力的方法.

主要方法:

文献综述侧重于CRPC中的AR变体.
对天然化合物及其类似物作为AR和AR拼接变体抑制剂的研究分析.
检查在临床前和临床环境中研究天然衍生物的疗效和局限性的研究.

主要成果:

AR拼接变种,特别是AR-V7,与CRPC的治疗耐药性有关.
自然化合物及其衍生物显示出选择性抑制AR拼接变体的潜力.
尽管存在生物可用性和疗效限制,但天然衍生物在治疗耐化学性前列腺癌方面表现有前途.

结论:

自然化合物为开发针对AR驱动前列腺癌的新疗法提供了一个有希望的途径,特别是在耐药形式中.
以天然衍生物向AR拼接变体可能会为传统治疗提供毒性较低的替代方案.
进一步研究优化天然化合物的生物可用性和疗效对于临床转化至关重要.

关键词:

这些AR-SVs.在AR-V7中使用AR-V7.雄激素受体的受体雄激素受体雄激素受体拼接变体的变体割抵抗性前列腺癌是什么?化学抗药性化学抗药性是一种抗药性.天然化合物是一种自然化合物.营养保健品营养保健品前列腺癌是什么意思前列腺癌是什么意思拼接的变种拼接的变种

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

相关概念视频

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...